Is NewAmsterdam Pharma (NAMS) Undervalued After Its First Obicetrapib Approval?
NewAmsterdam Pharma (NasdaqGM:NAMS) just crossed an important milestone after the European Commission approved Ubeslo and Evlarco, providing the first global regulatory green light for its cholesterol drug obicetrapib.
The European decision lands after a rough stretch for NewAmsterdam Pharma’s Nasdaq listing, with the share price down 16.33% over the past 30 days and 28.53% over 90 days, even though the 3 year total shareholder return is very large. Recent trading tells a different short term story, with a 7 day share price return of 10.21% and a 1 day move of 3.28% to US$23.32 that points to momentum rebuilding as investors react to the first global approval for obicetrapib.
Look beyond NewAmsterdam Pharma and this EC approval by reviewing other late-stage therapeutics players with upcoming catalysts in the curated 16 high quality undiscovered gems
NewAmsterdam Pharma just swung from a weak few months to a sharp post approval bounce. The real question now is whether that first spike is worth chasing or if it is better to wait for a cooler entry before running the numbers.
Most Popular Narrative: 54% Undervalued
Against the last close at $23.32, the most followed narrative frames NewAmsterdam Pharma as trading at a steep discount to an implied fair value near $50.92. This puts the focus squarely on whether the long term obicetrapib story holds up.
The current valuation implies that NewAmsterdam Pharma already reflects expectations for a successful PREVAIL readout and a commercially meaningful outcomes label, leaving limited room for error but potential upside if the broader cardiometabolic and Alzheimer’s prevention strategy progresses as anticipated.
See why 1 investors see NewAmsterdam Pharma as 54% undervalued.
Result: Fair Value of $50.92 (UNDERVALUED)
Still, NewAmsterdam Pharma faces real swing factors, including the risk that PREVAIL fails to confirm a meaningful cardiovascular benefit and that continued equity issuance dilutes future per share results.
Find out about the key risks to this NewAmsterdam Pharma narrative.
Next Steps
If the tone of this NewAmsterdam Pharma story feels optimistic, take a moment to pressure test the numbers yourself and consider acting while sentiment is taking shape. To see what investors find most attractive right now, review the 3 key rewards.
Looking for more NewAmsterdam Pharma style investment ideas?
Do not stop with NewAmsterdam Pharma. Use the Simply Wall Street Screener to quickly surface fresh opportunities that match your risk profile and return goals in minutes.
- Target high quality potential bargains by scanning the market for mispriced opportunities using the 29 high quality undervalued stocks.
- Protect your capital first and search for businesses with resilient financial profiles in the 30 resilient stocks with low risk scores.
- Seek hidden potential by focusing your research on underfollowed companies with strong fundamentals in the 16 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com